PEP/NEWS — Peptide intel. Daily.

🎯 What happens when women start losing sensation, arousal, or pleasure with age—and is there anything that can actually help? In this episode of The SexMD Podcast, Dr. Debra Durst sits down with sex educator, author, and podcaster Susan B

Get Strong with Me Inside my NEW Strength Vault: ⁠https://www.drtyna.com/offers/G33fSdvS/checkout EP. 269: Moving was one of the biggest decisions I've ever made, and honestly, one of the best. In this episode, I'm sitting down with my re

Lifespan.io's June 2026 roundup covers a month where genomic-level aging work took center stage. The summary includes the Thalion Initiative and a range of new longevity research worth tracking.

Researchers found a non-coding RNA strand that is unique to primates and makes cellular senescence worse. It does not produce proteins itself — but it appears to amplify the inflammatory effects of aging cells.

A new study links accelerated biological aging to rising rates of solid cancers in younger adults. Each successive generation shows a wider gap — suggesting the trend is not simply better detection.

Researchers tracked aging trajectories across specific cell types and found they could predict disease onset — including Alzheimer's and lung cancer — with meaningful accuracy. It is a step toward tissue-specific biomarkers that beat whole-body aging clocks.

New biomarker results from NeuroSense suggest its PrimeC compound may act on neurodegeneration pathways shared across ALS, Alzheimer's, and Parkinson's. If the signal holds, it supports a multi-target approach over disease-specific silos.

Researchers confirmed that UV-induced age spots contain a higher burden of senescent cells. This adds mechanistic weight to the idea that clearing senescent cells could reverse visible photoaging — not just extend lifespan metrics.

Bryan Johnson outlines four cardiovascular protocols behind his reported vascular age equivalent to a late-teen. The post leans on measurable biomarkers rather than anecdote — worth reviewing for anyone tracking vascular function alongside peptide protocols.

NeuroAge Therapeutics is running a six-month contest where participants are scored on a clinical-grade aging panel at baseline and again six months later. It is an unusual format — but it creates real incentive to actually test interventions against hard biological markers.

Repair Bio's REP-0003 earned FDA Rare Disease Endpoint Pathway eligibility for inherited high cholesterol. The rare-disease route could accelerate data collection on a therapy designed to actually reverse arterial plaque — not just slow its growth.

The third installment in Research Vials' cancer series tackles the hardest questions: what GH secretagogues mean for cancer risk, when washout periods are warranted, and where the evidence actually supports continued use. Essential reading for anyone using growth hormone peptides long-term.

Before evaluating whether any peptide raises or lowers cancer risk, you need to understand how tumors actually develop. This foundation piece covers the key pathways — PI3K, mTOR, IGF-1 signaling — that come up repeatedly in peptide-cancer research.

Peter Attia reviews metformin's uneven cancer record — failed in prostate cancer and several others, with a few notable exceptions. His conclusion is precision over generalization: the drug is not a universal cancer shield.